2024.12.22 (일)

  • 맑음동두천 -1.7℃
  • 맑음강릉 1.9℃
  • 맑음서울 -0.4℃
  • 맑음대전 1.5℃
  • 맑음대구 1.8℃
  • 맑음울산 3.2℃
  • 구름조금광주 2.6℃
  • 맑음부산 4.0℃
  • 구름많음고창 2.2℃
  • 흐림제주 5.6℃
  • 맑음강화 -1.2℃
  • 맑음보은 -1.4℃
  • 맑음금산 0.7℃
  • 구름많음강진군 4.3℃
  • 맑음경주시 2.5℃
  • 맑음거제 4.7℃
기상청 제공

소화기내과

지방간질환의 관리

이화여자대학교 의과대학 부속 목동병원 간센터/췌장·담도센터 김휘영 교수


* 출처 : 이대목동병원



이화여자대학교 의과대학 부속 목동병원 간센터/췌장ㆍ담도센터

김휘영 교수


진료과: 간센터/췌장ㆍ담도센터

전문진료분야: 간암, 간경변, B형 간염, C형 간염, 급성 간염, 알코올간질환, 지방간, 독성 간염, 자가면역간질환, 간기능검사이상


학력 사항

서울대학교 의과대학 의학과 졸업 

서울대학교 의과대학 대학원 석사 

서울대학교 의과대학 대학원 박사 


교육 및 연구 경력

현) 이화여자대학교 의과대학 내과학교실 이대목동병원 조교수


기타 학술 관련 경력

2010-2011 대한간학회 섭외위원 

2011 대한간학회 만성 B형 간염 진료 가이드라인 개정위원 

2013-2014 대한간암학회 학술위원 

2014 대한간암학회-국립암센터 간세포암종 진료 가이드라인 개정위원


주요 업적

1. Lee JH, Cho Y, Kim HY, et al. Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. Annals of surgery 2016. 


2. Park S, Kim HY, Kim H, et al. Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy: Potential Markers for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome. Medicine 2016;95:e2454. 


3. Yu SJ, Kim W, Kim D, et al. Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Medicine 2015;94:e2159. 


4. Kim HY, Chang Y, Park JY, et al. Characterization of acute-on-chronic liver failure and prediction of mortality in Asian patients with active alcoholism. Journal of gastroenterology and hepatology 2015. 


5. Kim HY, Jin EH, Kim W, et al. The Role of Spleen Stiffness in Determining the Severity and Bleeding Risk of Esophageal Varices in Cirrhotic Patients. Medicine 2015;94:e1031. 


6. Chung KH, Kim W, Kim BG, et al. Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay. Gut and liver 2015. 


7. Hwang SY, Yu SJ, Lee JH, Kim HY, Kim YJ. Reduction of oxidative stress attenuates lipoapoptosis exacerbated by hypoxia in human hepatocytes. Int J Mol Sci 2015;16:3323-34. 


8. Kim HY, Kim W. Chemotherapy-related reactivation of hepatitis B infection: updates in 2013. World journal of gastroenterology : WJG 2014;20:14581-8. 


9. Kim HY, Park JW. Clinical Trials of Combined Molecular Targeted Therapy and Locoregional Therapy in Hepatocellular Carcinoma: Past, Present, and Future. Liver cancer 2014;3:9-17. 


10. Kim HY, Yoon JH, Lee HS, et al. MicroRNA-196A-2 polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B. Journal of medical virology 2014;86:446-53. 


11. Lee M, Oh S, Lee HJ, et al. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. Journal of viral hepatitis 2014;21:873-81. 


12. Lee JH, Kim HY, Kim YJ, Yoon JH, Chung JW, Lee HS. BCLC System Provides the Best Discrimination Ability for Survival of Untreated Hepatocellular Carcinoma Patients in an HBV-endemic Area. Journal of gastroenterology and hepatology 2014. 


13. Lee M, Kim W, Choi Y, et al. Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis. PLoS One 2014;9:e100870. 


14. Joo SK, Kim JH, Oh S, et al. Prospective Comparison of Noninvasive Fibrosis Assessment to Predict Advanced Fibrosis or Cirrhosis in Asian Patients With Hepatitis C. Journal of clinical gastroenterology 2014. 


15. Kim HY, Park JW, Joo J, et al. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. Journal of gastroenterology and hepatology 2013;28:1756-61.


16. Kim YJ, Kim HY, Lee JH, et al. A genome-wide association study identified new variants associated with the risk of chronic hepatitis B. Human molecular genetics 2013;22:4233-8. 


17. Jun DW, Kim BI, Cho YK, et al. Efficacy and safety of entecavir plus carnitine complex (GODEX(R)) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study. Clinical and molecular hepatology 2013;19:165-72. 


18. Kim JW, Jeong JB, Lee KL, et al. Comparison of clinical outcomes between endoscopic and radiologic placement of self-expandable metal stent in patients with malignant colorectal obstruction. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2013;61:22-9. 


19. Seo JY, Kim W, Kwon JH, et al. Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation. Liver international : official journal of the International Association for the Study of the Liver 2013;33:884-93. 


20. Park JW, Koh YH, Kim HB, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. Journal of hepatology 2012;56:1336-42. 


21. Kim HY, Kwon HD, Jang TS, Lim J, Lee HS. Mathematical Modeling of Triphasic Viral Dynamics in Patients with HBeAg-Positive Chronic Hepatitis B Showing Response to 24-Week Clevudine Therapy. PLOS ONE 2012;7:e50377. 


22. Kim HY, Park JW, Joo J, et al. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma. Journal of gastroenterology and hepatology 2012;27:1051-6. 


23. Kim HY, Park JW, Nam BH, et al. Survival of patients with advanced hepatocellular carcinoma: Sorafenib versus other treatments. Journal of gastroenterology and hepatology 2011;26:1612-8. 


24. Kim HY, Park JW. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone. Dig Dis 2011;29:303-9. 


25. Kim YJ, Kim HY, Kim JS, et al. Putative association of transforming growth factor-alpha polymorphisms with clearance of hepatitis B virus and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Journal of viral hepatitis 2010;17:518-26. 


26. Chung GE, Kim W, Lee KL, et al. Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. Digestive diseases and sciences 2011;56:2130-6. 


27. Chung GE, Yoon JH, Lee JH, et al. Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. Oncology reports 2011;25:1739-46.


28. Kwak MS, Lee JH, Chung GE, et al. Low P2/MS value is an independent risk factor for early recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. Hepato-gastroenterology 2011;58:147-52. 


29. Lee JH, Yoon JH, Lee YJ, et al. Mesalamine-induced B7-H1 expression on hepatic stellate cells attenuates autoimmune liver injury. Hepatology research : the official journal of the Japan Society of Hepatology 2011;41:79-86. 


30. Lee JH, Chung GE, Yu SJ, et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. Journal of clinical gastroenterology 2011;45:69-75. 


31. Lee JH, Yoon JH, Yu SJ, et al. Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells. Cancer letters 2010;295:229-35. 


32. Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011;258:627-34. 

관련기사



배너
배너